Total trials
75
Active
16
Phase 3
3
Total enrollment
14,494
Pipeline matrix
Showing 6 of 6 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Eptinezumab 100 or 300 mg ev | — | — | — | — | — | 2 | |
| Rimegepant 75 mg | — | — | — | — | — | 1 | |
| Rimegepant 75 MG Disintegrating Oral | — | — | — | — | — | 1 | |
| Atogepant 60 mg | — | — | — | — | — | 1 | |
| enfortumab vedotin | — | — | — | — | — | 1 | |
| PEMBROLIZUMAB | — | — | — | — | — | 1 |
Next readouts
- 2024-06-15
- 2025-11-30
- 2026-10-30
- 2027-01-01
- 2027-09-01
Top conditions
- Migraine7
- Migraine With Aura5
- Migraine Without Aura5
- Chronic Migraine5
- Cystic Fibrosis4
- Periodontitis3
- Bladder Cancer3
- Prostatic Hyperplasia3
Frequently asked questions about University of Florence
- How many clinical trials does University of Florence have on ClinicalTrials.gov?
- University of Florence is listed as the lead sponsor on 75 clinical trials in ClinicalTrials.gov, 16 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Florence's trials are in Phase 3?
- 3 of University of Florence's trials are in Phase 3, spread across 6 active drug programs.
- What therapeutic areas does University of Florence focus on?
- University of Florence's most-studied conditions on ClinicalTrials.gov are Migraine, Migraine With Aura, Migraine Without Aura, Chronic Migraine, Cystic Fibrosis.
- When are University of Florence's next clinical trial readouts?
- University of Florence has 5 upcoming primary-completion readouts tracked here; the soonest is “Gepant treAtments: EffectIveNess and tolERability (GAINER)”, expected around 2024-06-15.